Dr. Christine M. Bestvina
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
21 reported clinical trials
38 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage III
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Christine M. Bestvina is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Durvalumab + Radiation
for Small Cell Lung Cancer
This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy has been approved by the Food and Drug Administration (FDA) for the treatment of small cell lung cancer along with chemotherapy. This study is testing the addition of radiation to durvalumab and chemotherapy.
Recruiting1 award Phase 214 criteria
More about Christine M. Bestvina
Clinical Trial Related6 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Christine M. Bestvina has experience with
- Carboplatin
- Pemetrexed
- Pembrolizumab
- Nivolumab
- Paclitaxel
- Durvalumab
Breakdown of trials Christine M. Bestvina has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Solid Tumors
Parotid Gland Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Christine M. Bestvina specialize in?
Is Christine M. Bestvina currently recruiting for clinical trials?
Are there any treatments that Christine M. Bestvina has studied deeply?
What is the best way to schedule an appointment with Christine M. Bestvina?
What is the office address of Christine M. Bestvina?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.